Kura Oncology

Kura hit as FDA slaps partial hold on leukaemia trial

Share in Kura Oncology have come under pressure after a patient death in a clinical trial of the US biotech’s acute myeloid leukaemia (AML) therapy KO-539, provisionally attributed to a side effect that plagues other drugs used to treat the cancer. The FDA has placed the trial on partial hold, meaning that patients already in …

Kura hit as FDA slaps partial hold on leukaemia trial Read More »

Patient death prompts clinical trial pause for Kura Oncology leukemia drug

The FDA placed a partial clinical hold on a Kura Oncology leukemia drug following the death of one patient in the early-stage study. Kura executives said the death may be related to differentiation syndrome, a known complication of leukemia therapies.